[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQ2sLu2w2nVsxXA4tp0cH_SMjlPgt0ei0aS9liab2Nmw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"Mclean Hospital",[4],180,false,35,7,15433,13,105,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Major Depressive Disorder",23,{"name":18,"count":19},"Bipolar Disorder",20,{"name":21,"count":22},"Depression",14,{"name":24,"count":25},"Schizophrenia",12,{"name":27,"count":25},"Nicotine Dependence",{"name":29,"count":25},"Bipolar Depression",{"name":31,"count":32},"Psychosis",9,{"name":34,"count":32},"Schizoaffective Disorder",[36,41,46,51,56,61,64,69,74,79],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04430517","Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment\u002FAlzheimer's Dementia","2026-05-15","Nicotinamide riboside",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06477406","Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis","2026-06","Cannabidiol",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05837104","Efficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder","2026-10","Magnesium vitamin B6",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05630963","Beyond Monoamines: The Role of the Nociceptin\u002FOrphanin FQ Receptor in Major Depression","2026-10-28","PET radiotracer",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT04075435","Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia","2026-12","high CBD\u002Flow THC sublingual solution",{"nctId":62,"briefTitle":63,"date":59,"intervention":45},"NCT05457465","Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06876129","Pharmacologic Augmentation of TMS for Depression With D-serine","2026-12-26","D-serine",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06191965","MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction","2027-01-31","MitoQ",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT05232032","Pharmaco-Neuroimaging Studies of Approach\u002FAvoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation","2027-03-31","Nociceptin Receptor Antagonist",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT07460947","A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder","2027-06","D-Cycloserine",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,118,178,225,260,282,300,321,355,386,408,426,474,495,519,543,572,590,614,641,665,691,715,741,759,784,808,841,873,898,921,944,969,990,1014,1038,1056,1080,1102,1138,1161,1187,1205,1229,1252,1276,1309,1327,1345,1389,1415,1437,1468,1501,1533,1565,1592,1617,1643,1668,1686,1711,1738,1756,1781,1803],{"intervention":73,"totalTrials":93,"cells":94},1,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":114,"NA":116},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":93,"soonestReadout":72},[104],{"nctId":70,"briefTitle":71,"status":105,"phases":106,"primaryCompletion":72,"completion":72,"start":107,"enrollment":108,"conditions":109,"interventions":113},"RECRUITING",[87,88],"2024-06-01",100,[110,111,112],"Schizophrenia and Related Disorders","Mitochondrial Alteration","Cognitive Impairment",[73],{"trials":115,"activeCount":97},[],{"trials":117,"activeCount":97},[],{"intervention":83,"totalTrials":119,"cells":120},4,{"EARLY_PHASE1":121,"PHASE1":149,"PHASE2":151,"PHASE3":172,"PHASE4":174,"NA":176},{"trials":122,"activeCount":93,"soonestReadout":140},[123,136],{"nctId":124,"briefTitle":125,"status":126,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":133},"NCT02304432","Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine","COMPLETED",[85],"2016-09-30","2017-07-31","2015-09-27",2,[24,18],[134,135,134],"D-cycloserine","DCS or placebo",{"nctId":137,"briefTitle":138,"status":105,"phases":139,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":145},"NCT07560878","Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression",[85],"2030-12","2026-03-11",80,[144],"Major Depression",[83,146,147,148],"Memantine","Lorazepam","Baclofen",{"trials":150,"activeCount":97},[],{"trials":152,"activeCount":131,"soonestReadout":82},[153,161],{"nctId":80,"briefTitle":81,"status":154,"phases":155,"primaryCompletion":82,"completion":156,"start":157,"enrollment":19,"conditions":158,"interventions":160},"NOT_YET_RECRUITING",[86,87],"2027-12","2026-05",[159],"Borderline Personality Disorder (BPD)",[83],{"nctId":162,"briefTitle":163,"status":154,"phases":164,"primaryCompletion":165,"completion":166,"start":167,"enrollment":108,"conditions":168,"interventions":170},"NCT07593222","Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder",[86,87],"2030-12-01","2031-06-30","2026-07-01",[144,169],"Healthy Participants",[134,171],"Dextromethophan",{"trials":173,"activeCount":97},[],{"trials":175,"activeCount":97},[],{"trials":177,"activeCount":97},[],{"intervention":45,"totalTrials":119,"cells":179},{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":194,"PHASE3":219,"PHASE4":221,"NA":223},{"trials":181,"activeCount":97},[],{"trials":183,"activeCount":97},[184],{"nctId":185,"briefTitle":186,"status":126,"phases":187,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":193},"NCT03102918","Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder",[86],"2017-08-30","2016-02-20",10,[192],"Cannabis Use Disorder",[45],{"trials":195,"activeCount":131,"soonestReadout":44},[196,203,213],{"nctId":42,"briefTitle":43,"status":105,"phases":197,"primaryCompletion":44,"completion":44,"start":198,"enrollment":199,"conditions":200,"interventions":202},[87],"2024-02-27",30,[201],"Endometriosis",[45],{"nctId":204,"briefTitle":205,"status":206,"phases":207,"primaryCompletion":208,"completion":208,"start":209,"enrollment":131,"conditions":210,"interventions":212},"NCT05753007","A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients","TERMINATED",[87],"2025-02-11","2024-02-15",[211],"Glioblastoma",[45],{"nctId":62,"briefTitle":63,"status":105,"phases":214,"primaryCompletion":59,"completion":59,"start":215,"enrollment":216,"conditions":217,"interventions":218},[87],"2023-06-01",25,[18],[45],{"trials":220,"activeCount":97},[],{"trials":222,"activeCount":97},[],{"trials":224,"activeCount":97},[],{"intervention":78,"totalTrials":131,"cells":226},{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":254,"PHASE4":256,"NA":258},{"trials":228,"activeCount":97},[],{"trials":230,"activeCount":97},[],{"trials":232,"activeCount":93,"soonestReadout":77},[233,246],{"nctId":234,"briefTitle":235,"status":236,"phases":237,"primaryCompletion":238,"completion":239,"start":240,"enrollment":97,"conditions":241,"interventions":245},"NCT06786637","Investigating the Protective Impact of LY-2940094 on Stress-induced Depression- and Anxiety-related Phenotypes in Humans","WITHDRAWN",[87],"2026-01","2026-08","2025-06",[242,243,244],"Depression - Major Depressive Disorder","Anxiety","Stress",[78],{"nctId":75,"briefTitle":76,"status":105,"phases":247,"primaryCompletion":77,"completion":77,"start":248,"enrollment":249,"conditions":250,"interventions":253},[87],"2025-02-01",112,[251,252],"Depressive Disorder, Major","Anxiety Disorder",[78],{"trials":255,"activeCount":97},[],{"trials":257,"activeCount":97},[],{"trials":259,"activeCount":97},[],{"intervention":50,"totalTrials":93,"cells":261},{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":276,"PHASE4":278,"NA":280},{"trials":263,"activeCount":97},[],{"trials":265,"activeCount":97},[],{"trials":267,"activeCount":93,"soonestReadout":49},[268],{"nctId":47,"briefTitle":48,"status":105,"phases":269,"primaryCompletion":49,"completion":49,"start":270,"enrollment":271,"conditions":272,"interventions":275},[87],"2023-12-13",40,[273,274,244],"Bipolar I Disorder","Depression, Anxiety",[50],{"trials":277,"activeCount":97},[],{"trials":279,"activeCount":97},[],{"trials":281,"activeCount":97},[],{"intervention":171,"totalTrials":93,"cells":283},{"EARLY_PHASE1":284,"PHASE1":286,"PHASE2":288,"PHASE3":294,"PHASE4":296,"NA":298},{"trials":285,"activeCount":97},[],{"trials":287,"activeCount":97},[],{"trials":289,"activeCount":93,"soonestReadout":165},[290],{"nctId":162,"briefTitle":163,"status":154,"phases":291,"primaryCompletion":165,"completion":166,"start":167,"enrollment":108,"conditions":292,"interventions":293},[86,87],[144,169],[134,171],{"trials":295,"activeCount":97},[],{"trials":297,"activeCount":97},[],{"trials":299,"activeCount":97},[],{"intervention":68,"totalTrials":93,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":313,"PHASE3":315,"PHASE4":317,"NA":319},{"trials":303,"activeCount":97},[],{"trials":305,"activeCount":93,"soonestReadout":67},[306],{"nctId":65,"briefTitle":66,"status":105,"phases":307,"primaryCompletion":67,"completion":308,"start":309,"enrollment":310,"conditions":311,"interventions":312},[86],"2027-04-01","2025-04-01",60,[21],[68],{"trials":314,"activeCount":97},[],{"trials":316,"activeCount":97},[],{"trials":318,"activeCount":97},[],{"trials":320,"activeCount":97},[],{"intervention":322,"totalTrials":131,"cells":323},"Nicotinamide Riboside",{"EARLY_PHASE1":324,"PHASE1":335,"PHASE2":337,"PHASE3":339,"PHASE4":341,"NA":353},{"trials":325,"activeCount":93,"soonestReadout":39},[326],{"nctId":37,"briefTitle":38,"status":327,"phases":328,"primaryCompletion":39,"completion":39,"start":329,"enrollment":330,"conditions":331,"interventions":334},"ACTIVE_NOT_RECRUITING",[85],"2022-03-02",50,[332,333],"Mild Cognitive Impairment","Mild Alzheimer Disease",[40],{"trials":336,"activeCount":97},[],{"trials":338,"activeCount":97},[],{"trials":340,"activeCount":97},[],{"trials":342,"activeCount":97},[343],{"nctId":344,"briefTitle":345,"status":206,"phases":346,"primaryCompletion":347,"completion":347,"start":348,"enrollment":349,"conditions":350,"interventions":352},"NCT03151707","The Effects of Nicotinamide Riboside Supplementation on Brain NAD+\u002FNADH Ratio and Bioenergetics",[89],"2022-09-30","2017-10-01",11,[351],"Healthy",[322],{"trials":354,"activeCount":97},[],{"intervention":147,"totalTrials":131,"cells":356},{"EARLY_PHASE1":357,"PHASE1":363,"PHASE2":365,"PHASE3":380,"PHASE4":382,"NA":384},{"trials":358,"activeCount":93,"soonestReadout":140},[359],{"nctId":137,"briefTitle":138,"status":105,"phases":360,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":361,"interventions":362},[85],[144],[83,146,147,148],{"trials":364,"activeCount":97},[],{"trials":366,"activeCount":97},[367],{"nctId":368,"briefTitle":369,"status":126,"phases":370,"primaryCompletion":371,"completion":371,"start":372,"enrollment":373,"conditions":374,"interventions":378},"NCT00431184","Effects of Pentazocine Versus Lorazepam on Manic Symptoms",[87],"2011-03","2007-01",19,[18,34,375,376,377],"Manic Disorder","Mania","Manic State",[379,147],"Pentazocine",{"trials":381,"activeCount":97},[],{"trials":383,"activeCount":97},[],{"trials":385,"activeCount":97},[],{"intervention":60,"totalTrials":93,"cells":387},{"EARLY_PHASE1":388,"PHASE1":398,"PHASE2":400,"PHASE3":402,"PHASE4":404,"NA":406},{"trials":389,"activeCount":93,"soonestReadout":59},[390],{"nctId":57,"briefTitle":58,"status":327,"phases":391,"primaryCompletion":59,"completion":59,"start":392,"enrollment":25,"conditions":393,"interventions":397},[85],"2021-01-11",[394,243,395,396],"Alzheimer Disease","Agitation,Psychomotor","Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease",[60],{"trials":399,"activeCount":97},[],{"trials":401,"activeCount":97},[],{"trials":403,"activeCount":97},[],{"trials":405,"activeCount":97},[],{"trials":407,"activeCount":97},[],{"intervention":148,"totalTrials":93,"cells":409},{"EARLY_PHASE1":410,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":422,"NA":424},{"trials":411,"activeCount":93,"soonestReadout":140},[412],{"nctId":137,"briefTitle":138,"status":105,"phases":413,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":414,"interventions":415},[85],[144],[83,146,147,148],{"trials":417,"activeCount":97},[],{"trials":419,"activeCount":97},[],{"trials":421,"activeCount":97},[],{"trials":423,"activeCount":97},[],{"trials":425,"activeCount":97},[],{"intervention":146,"totalTrials":119,"cells":427},{"EARLY_PHASE1":428,"PHASE1":434,"PHASE2":444,"PHASE3":446,"PHASE4":448,"NA":461},{"trials":429,"activeCount":93,"soonestReadout":140},[430],{"nctId":137,"briefTitle":138,"status":105,"phases":431,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":432,"interventions":433},[85],[144],[83,146,147,148],{"trials":435,"activeCount":97},[436],{"nctId":437,"briefTitle":438,"status":126,"phases":439,"primaryCompletion":440,"completion":440,"start":441,"enrollment":25,"conditions":442,"interventions":443},"NCT01392287","Treatment Resistant Geriatric Depression in Primary Care",[86],"2012-04","2010-05",[15],[146],{"trials":445,"activeCount":97},[],{"trials":447,"activeCount":97},[],{"trials":449,"activeCount":97},[450],{"nctId":451,"briefTitle":452,"status":126,"phases":453,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":459},"NCT00330655","An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder",[89],"2007-07","2006-05",15,[458],"Binge Eating Disorder",[460],"memantine",{"trials":462,"activeCount":97},[463],{"nctId":464,"briefTitle":465,"status":126,"phases":466,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":470,"interventions":473},"NCT01038128","An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder",[90],"2011-05","2009-12",5,[471,472],"Bulimia Nervosa","Body Dysmorphic Disorder",[146],{"intervention":55,"totalTrials":93,"cells":475},{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":486},{"trials":477,"activeCount":97},[],{"trials":479,"activeCount":97},[],{"trials":481,"activeCount":97},[],{"trials":483,"activeCount":97},[],{"trials":485,"activeCount":97},[],{"trials":487,"activeCount":93,"soonestReadout":54},[488],{"nctId":52,"briefTitle":53,"status":105,"phases":489,"primaryCompletion":54,"completion":490,"start":491,"enrollment":492,"conditions":493,"interventions":494},[],"2027-02-28","2021-12-29",228,[15],[55],{"intervention":496,"totalTrials":93,"cells":497},"Bupropion",{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":506,"NA":517},{"trials":499,"activeCount":97},[],{"trials":501,"activeCount":97},[],{"trials":503,"activeCount":97},[],{"trials":505,"activeCount":97},[],{"trials":507,"activeCount":97},[508],{"nctId":509,"briefTitle":510,"status":126,"phases":511,"primaryCompletion":512,"completion":512,"start":347,"enrollment":513,"conditions":514,"interventions":515},"NCT05537584","SMART Trial to Predict Anhedonia Response to Antidepressant Treatment",[89],"2025-08-26",133,[15],[516,496],"Sertraline",{"trials":518,"activeCount":97},[],{"intervention":520,"totalTrials":93,"cells":521},"Testosterone gel",{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":528,"PHASE4":530,"NA":541},{"trials":523,"activeCount":97},[],{"trials":525,"activeCount":97},[],{"trials":527,"activeCount":97},[],{"trials":529,"activeCount":97},[],{"trials":531,"activeCount":97},[532],{"nctId":533,"briefTitle":534,"status":126,"phases":535,"primaryCompletion":536,"completion":537,"start":538,"enrollment":108,"conditions":539,"interventions":540},"NCT00304746","AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment",[89],"2008-12","2009-04","2006-04",[251],[520],{"trials":542,"activeCount":97},[],{"intervention":544,"totalTrials":93,"cells":545},"Simvastatin",{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":552,"PHASE4":554,"NA":570},{"trials":547,"activeCount":97},[],{"trials":549,"activeCount":97},[],{"trials":551,"activeCount":97},[],{"trials":553,"activeCount":97},[],{"trials":555,"activeCount":97},[556],{"nctId":557,"briefTitle":558,"status":126,"phases":559,"primaryCompletion":560,"completion":561,"start":562,"enrollment":563,"conditions":564,"interventions":568},"NCT02188121","Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients",[89],"2020-10","2021-10","2015-02",227,[565,24,34,18,566,15,567],"Serious Mental Illness","Cardiovascular Disease","Psychosis NOS",[544,569],"Losartan",{"trials":571,"activeCount":97},[],{"intervention":569,"totalTrials":93,"cells":573},{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":580,"PHASE4":582,"NA":588},{"trials":575,"activeCount":97},[],{"trials":577,"activeCount":97},[],{"trials":579,"activeCount":97},[],{"trials":581,"activeCount":97},[],{"trials":583,"activeCount":97},[584],{"nctId":557,"briefTitle":558,"status":126,"phases":585,"primaryCompletion":560,"completion":561,"start":562,"enrollment":563,"conditions":586,"interventions":587},[89],[565,24,34,18,566,15,567],[544,569],{"trials":589,"activeCount":97},[],{"intervention":591,"totalTrials":93,"cells":592},"Lisdexamfetamine Dimesylate",{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":601,"NA":612},{"trials":594,"activeCount":97},[],{"trials":596,"activeCount":97},[],{"trials":598,"activeCount":97},[],{"trials":600,"activeCount":97},[],{"trials":602,"activeCount":97},[603],{"nctId":604,"briefTitle":605,"status":126,"phases":606,"primaryCompletion":607,"completion":608,"start":609,"enrollment":8,"conditions":610,"interventions":611},"NCT01148979","Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.",[89],"2014-09","2014-10","2010-09",[15],[591],{"trials":613,"activeCount":97},[],{"intervention":615,"totalTrials":93,"cells":616},"Sodium Naproxen",{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":625,"NA":639},{"trials":618,"activeCount":97},[],{"trials":620,"activeCount":97},[],{"trials":622,"activeCount":97},[],{"trials":624,"activeCount":97},[],{"trials":626,"activeCount":97},[627],{"nctId":628,"briefTitle":629,"status":126,"phases":630,"primaryCompletion":631,"completion":631,"start":632,"enrollment":633,"conditions":634,"interventions":638},"NCT05900336","Non-Steroidal Anti-Inflammatory Drug (NSAID) Response and Central Sensitization of Pain in Women With Dysmenorrhea",[89],"2025-08-01","2024-03-25",70,[635,636,637],"Dysmenorrhea","Menstrual Pain","Non-steroidal Anti-inflammatory Drug",[615],{"trials":640,"activeCount":97},[],{"intervention":642,"totalTrials":93,"cells":643},"extended-release clonidine",{"EARLY_PHASE1":644,"PHASE1":646,"PHASE2":648,"PHASE3":650,"PHASE4":652,"NA":663},{"trials":645,"activeCount":97},[],{"trials":647,"activeCount":97},[],{"trials":649,"activeCount":97},[],{"trials":651,"activeCount":97},[],{"trials":653,"activeCount":97},[654],{"nctId":655,"briefTitle":656,"status":206,"phases":657,"primaryCompletion":658,"completion":658,"start":659,"enrollment":469,"conditions":660,"interventions":662},"NCT03065933","An Extended-Release Form of Clonidine as an Anti-Manic Agent: An Add-on, Open-Label Study",[89],"2013-01","2012-01",[661],"Bipolar Disorder, Mania",[642],{"trials":664,"activeCount":97},[],{"intervention":666,"totalTrials":93,"cells":667},"citalopram",{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":672,"PHASE3":674,"PHASE4":676,"NA":689},{"trials":669,"activeCount":97},[],{"trials":671,"activeCount":97},[],{"trials":673,"activeCount":97},[],{"trials":675,"activeCount":97},[],{"trials":677,"activeCount":97},[678],{"nctId":679,"briefTitle":680,"status":126,"phases":681,"primaryCompletion":682,"completion":682,"start":683,"enrollment":684,"conditions":685,"interventions":688},"NCT01557946","Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression",[89],"2015-09","2012-03",32,[686,687,15],"MDD","Citalopram",[666],{"trials":690,"activeCount":97},[],{"intervention":692,"totalTrials":93,"cells":693},"duloxetine",{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":700,"PHASE4":702,"NA":713},{"trials":695,"activeCount":97},[],{"trials":697,"activeCount":97},[],{"trials":699,"activeCount":97},[],{"trials":701,"activeCount":97},[],{"trials":703,"activeCount":97},[704],{"nctId":705,"briefTitle":706,"status":126,"phases":707,"primaryCompletion":708,"completion":708,"start":709,"enrollment":456,"conditions":710,"interventions":712},"NCT00401258","An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome",[89],"2008-02","2006-11",[711],"Irritable Bowel Syndrome",[692],{"trials":714,"activeCount":97},[],{"intervention":716,"totalTrials":93,"cells":717},"Dronabinol",{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":722,"PHASE3":724,"PHASE4":737,"NA":739},{"trials":719,"activeCount":97},[],{"trials":721,"activeCount":97},[],{"trials":723,"activeCount":97},[],{"trials":725,"activeCount":97},[726],{"nctId":727,"briefTitle":728,"status":206,"phases":729,"primaryCompletion":730,"completion":730,"start":731,"enrollment":25,"conditions":732,"interventions":735},"NCT01598896","Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia",[87,88],"2017-08","2012-05",[733,734],"Cannabis Dependence","Marijuana Dependence",[716,736],"Clonidine",{"trials":738,"activeCount":97},[],{"trials":740,"activeCount":97},[],{"intervention":736,"totalTrials":93,"cells":742},{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":755,"NA":757},{"trials":744,"activeCount":97},[],{"trials":746,"activeCount":97},[],{"trials":748,"activeCount":97},[],{"trials":750,"activeCount":97},[751],{"nctId":727,"briefTitle":728,"status":206,"phases":752,"primaryCompletion":730,"completion":730,"start":731,"enrollment":25,"conditions":753,"interventions":754},[87,88],[733,734],[716,736],{"trials":756,"activeCount":97},[],{"trials":758,"activeCount":97},[],{"intervention":760,"totalTrials":93,"cells":761},"Wellbutrin",{"EARLY_PHASE1":762,"PHASE1":764,"PHASE2":766,"PHASE3":768,"PHASE4":780,"NA":782},{"trials":763,"activeCount":97},[],{"trials":765,"activeCount":97},[],{"trials":767,"activeCount":97},[],{"trials":769,"activeCount":97},[770],{"nctId":771,"briefTitle":772,"status":126,"phases":773,"primaryCompletion":774,"completion":775,"start":776,"enrollment":684,"conditions":777,"interventions":779},"NCT00125957","The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression",[88],"2010-01","2011-12","2005-08",[21,15,778],"Unipolar Depression",[760],{"trials":781,"activeCount":97},[],{"trials":783,"activeCount":97},[],{"intervention":785,"totalTrials":93,"cells":786},"Nabilone",{"EARLY_PHASE1":787,"PHASE1":789,"PHASE2":791,"PHASE3":793,"PHASE4":804,"NA":806},{"trials":788,"activeCount":97},[],{"trials":790,"activeCount":97},[],{"trials":792,"activeCount":97},[],{"trials":794,"activeCount":97},[795],{"nctId":796,"briefTitle":797,"status":126,"phases":798,"primaryCompletion":799,"completion":799,"start":800,"enrollment":801,"conditions":802,"interventions":803},"NCT01347762","Nabilone for Cannabis Dependence: A Pilot Study",[87,88],"2017-06-09","2010-06",84,[733,734],[785],{"trials":805,"activeCount":97},[],{"trials":807,"activeCount":97},[],{"intervention":809,"totalTrials":131,"cells":810},"Citicoline",{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":835,"PHASE4":837,"NA":839},{"trials":812,"activeCount":97},[],{"trials":814,"activeCount":97},[],{"trials":816,"activeCount":97},[817,825],{"nctId":818,"briefTitle":819,"status":236,"phases":820,"primaryCompletion":821,"completion":821,"start":440,"enrollment":97,"conditions":822,"interventions":824},"NCT01591759","A Pilot Trial of Citicoline in Individuals With Mild Traumatic Brain Injury (mTBI)",[87],"2014-04",[823],"Traumatic Brain Injury",[809],{"nctId":826,"briefTitle":827,"status":126,"phases":828,"primaryCompletion":658,"completion":608,"start":829,"enrollment":830,"conditions":831,"interventions":833},"NCT00158249","Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals",[87],"2009-09",21,[832],"Marijuana Abuse",[834],"citicoline",{"trials":836,"activeCount":97},[],{"trials":838,"activeCount":97},[],{"trials":840,"activeCount":97},[],{"intervention":842,"totalTrials":131,"cells":843},"Nicotine Replacement Therapy",{"EARLY_PHASE1":844,"PHASE1":846,"PHASE2":848,"PHASE3":867,"PHASE4":869,"NA":871},{"trials":845,"activeCount":97},[],{"trials":847,"activeCount":97},[],{"trials":849,"activeCount":97},[850,859],{"nctId":851,"briefTitle":852,"status":206,"phases":853,"primaryCompletion":730,"completion":730,"start":854,"enrollment":855,"conditions":856,"interventions":858},"NCT01842334","D-cycloserine (DCS) Pretreatment + CBT + Nicotine Replacement Therapy for Smoking Cessation (DCS)",[86,87],"2013-04",22,[27,857],"Smoking Cessation",[842],{"nctId":860,"briefTitle":861,"status":126,"phases":862,"primaryCompletion":863,"completion":863,"start":864,"enrollment":25,"conditions":865,"interventions":866},"NCT01292642","Cognitive Behavioral Therapy and the Nicotine Transdermal Patch for Cannabis Dependence and Nicotine Dependence",[87],"2011-06","2009-08",[733,27],[842],{"trials":868,"activeCount":97},[],{"trials":870,"activeCount":97},[],{"trials":872,"activeCount":97},[],{"intervention":874,"totalTrials":93,"cells":875},"Puerarin, Placebo",{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":892,"PHASE4":894,"NA":896},{"trials":877,"activeCount":97},[],{"trials":879,"activeCount":97},[],{"trials":881,"activeCount":97},[882],{"nctId":883,"briefTitle":884,"status":126,"phases":885,"primaryCompletion":371,"completion":886,"start":887,"enrollment":888,"conditions":889,"interventions":891},"NCT00854724","Puerarin Effects on Alcohol Drinking",[87],"2011-07","2009-02",16,[890],"Alcohol Abuse",[874],{"trials":893,"activeCount":97},[],{"trials":895,"activeCount":97},[],{"trials":897,"activeCount":97},[],{"intervention":899,"totalTrials":93,"cells":900},"CBD",{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":915,"PHASE4":917,"NA":919},{"trials":902,"activeCount":97},[],{"trials":904,"activeCount":97},[],{"trials":906,"activeCount":97},[907],{"nctId":908,"briefTitle":909,"status":206,"phases":910,"primaryCompletion":911,"completion":911,"start":912,"enrollment":456,"conditions":913,"interventions":914},"NCT04286594","A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety",[87],"2023-08-24","2021-02-01",[243],[899],{"trials":916,"activeCount":97},[],{"trials":918,"activeCount":97},[],{"trials":920,"activeCount":97},[],{"intervention":922,"totalTrials":93,"cells":923},"Talwin Nx",{"EARLY_PHASE1":924,"PHASE1":926,"PHASE2":928,"PHASE3":938,"PHASE4":940,"NA":942},{"trials":925,"activeCount":97},[],{"trials":927,"activeCount":97},[],{"trials":929,"activeCount":97},[930],{"nctId":931,"briefTitle":932,"status":126,"phases":933,"primaryCompletion":934,"completion":536,"start":935,"enrollment":190,"conditions":936,"interventions":937},"NCT00125931","Effects of Pentazocine on Manic Symptoms",[87],"2008-08","2005-09",[18],[922],{"trials":939,"activeCount":97},[],{"trials":941,"activeCount":97},[],{"trials":943,"activeCount":97},[],{"intervention":945,"totalTrials":93,"cells":946},"Intranasal Insulin",{"EARLY_PHASE1":947,"PHASE1":949,"PHASE2":951,"PHASE3":963,"PHASE4":965,"NA":967},{"trials":948,"activeCount":97},[],{"trials":950,"activeCount":97},[],{"trials":952,"activeCount":97},[953],{"nctId":954,"briefTitle":955,"status":126,"phases":956,"primaryCompletion":957,"completion":957,"start":958,"enrollment":959,"conditions":960,"interventions":962},"NCT03943537","Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders",[87],"2024-02-23","2019-10-01",87,[31,24,961,273],"Schizo Affective Disorder",[945],{"trials":964,"activeCount":97},[],{"trials":966,"activeCount":97},[],{"trials":968,"activeCount":97},[],{"intervention":970,"totalTrials":93,"cells":971},"acetyl-l-carnitine PLUS alpha-lipoic acide",{"EARLY_PHASE1":972,"PHASE1":974,"PHASE2":976,"PHASE3":984,"PHASE4":986,"NA":988},{"trials":973,"activeCount":97},[],{"trials":975,"activeCount":97},[],{"trials":977,"activeCount":97},[978],{"nctId":979,"briefTitle":980,"status":126,"phases":981,"primaryCompletion":467,"completion":467,"start":934,"enrollment":271,"conditions":982,"interventions":983},"NCT00719706","The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder",[87],[29],[970],{"trials":985,"activeCount":97},[],{"trials":987,"activeCount":97},[],{"trials":989,"activeCount":97},[],{"intervention":991,"totalTrials":93,"cells":992},"Xenon",{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":1008,"PHASE4":1010,"NA":1012},{"trials":994,"activeCount":97},[],{"trials":996,"activeCount":97},[],{"trials":998,"activeCount":97},[999],{"nctId":1000,"briefTitle":1001,"status":236,"phases":1002,"primaryCompletion":1003,"completion":1003,"start":1004,"enrollment":97,"conditions":1005,"interventions":1007},"NCT02098148","Trial of Low-Dose Xenon For The Treatment Of Obsessive-Compulsive Disorder",[87],"2014-01","2013-11",[1006],"Obsessive-Compulsive Disorder",[991],{"trials":1009,"activeCount":97},[],{"trials":1011,"activeCount":97},[],{"trials":1013,"activeCount":97},[],{"intervention":1015,"totalTrials":93,"cells":1016},"Kudzu extract",{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1032,"PHASE4":1034,"NA":1036},{"trials":1018,"activeCount":97},[],{"trials":1020,"activeCount":97},[],{"trials":1022,"activeCount":97},[1023],{"nctId":1024,"briefTitle":1025,"status":236,"phases":1026,"primaryCompletion":682,"start":1027,"enrollment":97,"conditions":1028,"interventions":1031},"NCT01853293","Use of Kudzu Extract in the Study of Its Ability to Reduce Alcohol Drinking in Treatment Seeking Alcohol Dependent Persons",[87],"2014-03",[890,1029,1030],"Alcohol Dependence","Heavy Drinking Days",[1015],{"trials":1033,"activeCount":97},[],{"trials":1035,"activeCount":97},[],{"trials":1037,"activeCount":97},[],{"intervention":379,"totalTrials":93,"cells":1039},{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1050,"PHASE4":1052,"NA":1054},{"trials":1041,"activeCount":97},[],{"trials":1043,"activeCount":97},[],{"trials":1045,"activeCount":97},[1046],{"nctId":368,"briefTitle":369,"status":126,"phases":1047,"primaryCompletion":371,"completion":371,"start":372,"enrollment":373,"conditions":1048,"interventions":1049},[87],[18,34,375,376,377],[379,147],{"trials":1051,"activeCount":97},[],{"trials":1053,"activeCount":97},[],{"trials":1055,"activeCount":97},[],{"intervention":1057,"totalTrials":93,"cells":1058},"Glycine",{"EARLY_PHASE1":1059,"PHASE1":1061,"PHASE2":1063,"PHASE3":1074,"PHASE4":1076,"NA":1078},{"trials":1060,"activeCount":97},[],{"trials":1062,"activeCount":97},[],{"trials":1064,"activeCount":97},[1065],{"nctId":1066,"briefTitle":1067,"status":126,"phases":1068,"primaryCompletion":1069,"completion":1069,"start":1070,"enrollment":131,"conditions":1071,"interventions":1073},"NCT01720316","Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders",[87],"2017-05-31","2012-12-10",[1072,18],"Schizo-affective Disorder",[1057],{"trials":1075,"activeCount":97},[],{"trials":1077,"activeCount":97},[],{"trials":1079,"activeCount":97},[],{"intervention":1081,"totalTrials":93,"cells":1082},"taurine",{"EARLY_PHASE1":1083,"PHASE1":1085,"PHASE2":1087,"PHASE3":1096,"PHASE4":1098,"NA":1100},{"trials":1084,"activeCount":97},[],{"trials":1086,"activeCount":97},[],{"trials":1088,"activeCount":97},[1089],{"nctId":1090,"briefTitle":1091,"status":126,"phases":1092,"primaryCompletion":774,"completion":775,"start":1093,"enrollment":310,"conditions":1094,"interventions":1095},"NCT00217165","Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study",[87],"2005-04",[18,376,29],[1081],{"trials":1097,"activeCount":97},[],{"trials":1099,"activeCount":97},[],{"trials":1101,"activeCount":97},[],{"intervention":1103,"totalTrials":131,"cells":1104},"Amisulpride",{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1130,"PHASE3":1132,"PHASE4":1134,"NA":1136},{"trials":1106,"activeCount":97},[],{"trials":1108,"activeCount":97},[1109,1120],{"nctId":1110,"briefTitle":1111,"status":126,"phases":1112,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":1115,"conditions":1116,"interventions":1119},"NCT01701258","An Investigation of Early Life Stress and Depression",[86],"2017-05","2013-08",153,[1117,1118],"Major Depressive Disorder (MDD)","History of Childhood Sexual Abuse (CSA)",[1103],{"nctId":1121,"briefTitle":1122,"status":126,"phases":1123,"primaryCompletion":1124,"completion":1124,"start":1125,"enrollment":1126,"conditions":1127,"interventions":1128},"NCT01253421","The Effects of Dopamine on Reward Processing",[86],"2016-05","2012-02",159,[1117],[1129],"amisulpride",{"trials":1131,"activeCount":97},[],{"trials":1133,"activeCount":97},[],{"trials":1135,"activeCount":97},[],{"trials":1137,"activeCount":97},[],{"intervention":1139,"totalTrials":93,"cells":1140},"Lorcaserin",{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1153,"PHASE3":1155,"PHASE4":1157,"NA":1159},{"trials":1142,"activeCount":97},[],{"trials":1144,"activeCount":97},[1145],{"nctId":1146,"briefTitle":1147,"status":236,"phases":1148,"primaryCompletion":1149,"completion":1149,"start":1149,"enrollment":97,"conditions":1150,"interventions":1152},"NCT03266939","Rebalancing the Serotonergic System in Cocaine Dependence",[86],"2018-10-04",[1151],"Cocaine Dependence",[1139],{"trials":1154,"activeCount":97},[],{"trials":1156,"activeCount":97},[],{"trials":1158,"activeCount":97},[],{"trials":1160,"activeCount":97},[],{"intervention":1162,"totalTrials":93,"cells":1163},"Suvorexant 20 mg",{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1179,"PHASE3":1181,"PHASE4":1183,"NA":1185},{"trials":1165,"activeCount":97},[],{"trials":1167,"activeCount":97},[1168],{"nctId":1169,"briefTitle":1170,"status":1171,"phases":1172,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1175,"conditions":1176,"interventions":1177},"NCT03999099","Targeting Orexin to Treat Nicotine Dependence","UNKNOWN",[86],"2024-12-01","2019-09-26",45,[27],[1162,1178],"Suvorexant 10 mg",{"trials":1180,"activeCount":97},[],{"trials":1182,"activeCount":97},[],{"trials":1184,"activeCount":97},[],{"trials":1186,"activeCount":97},[],{"intervention":1178,"totalTrials":93,"cells":1188},{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1197,"PHASE3":1199,"PHASE4":1201,"NA":1203},{"trials":1190,"activeCount":97},[],{"trials":1192,"activeCount":97},[1193],{"nctId":1169,"briefTitle":1170,"status":1171,"phases":1194,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1175,"conditions":1195,"interventions":1196},[86],[27],[1162,1178],{"trials":1198,"activeCount":97},[],{"trials":1200,"activeCount":97},[],{"trials":1202,"activeCount":97},[],{"trials":1204,"activeCount":97},[],{"intervention":1206,"totalTrials":93,"cells":1207},"naltrexone",{"EARLY_PHASE1":1208,"PHASE1":1210,"PHASE2":1221,"PHASE3":1223,"PHASE4":1225,"NA":1227},{"trials":1209,"activeCount":97},[],{"trials":1211,"activeCount":97},[1212],{"nctId":1213,"briefTitle":1214,"status":126,"phases":1215,"primaryCompletion":1216,"completion":775,"start":1217,"enrollment":199,"conditions":1218,"interventions":1220},"NCT00567034","Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects",[86],"2010-12","2006-12",[24,1219],"Psychotic Disorders",[1206],{"trials":1222,"activeCount":97},[],{"trials":1224,"activeCount":97},[],{"trials":1226,"activeCount":97},[],{"trials":1228,"activeCount":97},[],{"intervention":1230,"totalTrials":93,"cells":1231},"Uridine",{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1244,"PHASE3":1246,"PHASE4":1248,"NA":1250},{"trials":1233,"activeCount":97},[],{"trials":1235,"activeCount":97},[1236],{"nctId":1237,"briefTitle":1238,"status":126,"phases":1239,"primaryCompletion":934,"completion":934,"start":709,"enrollment":1240,"conditions":1241,"interventions":1243},"NCT01261260","Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers",[86],33,[1242],"Healthy Male Subjects",[1230],{"trials":1245,"activeCount":97},[],{"trials":1247,"activeCount":97},[],{"trials":1249,"activeCount":97},[],{"trials":1251,"activeCount":97},[],{"intervention":1253,"totalTrials":93,"cells":1254},"Nicotine polacrilex",{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1268,"PHASE3":1270,"PHASE4":1272,"NA":1274},{"trials":1256,"activeCount":97},[],{"trials":1258,"activeCount":97},[1259],{"nctId":1260,"briefTitle":1261,"status":126,"phases":1262,"primaryCompletion":1263,"completion":1263,"start":562,"enrollment":1264,"conditions":1265,"interventions":1267},"NCT02346539","Effect of Nicotine on Brain Reward Pathways",[86],"2017-11",46,[1266],"Depressive Disorder",[1253],{"trials":1269,"activeCount":97},[],{"trials":1271,"activeCount":97},[],{"trials":1273,"activeCount":97},[],{"trials":1275,"activeCount":97},[],{"intervention":1277,"totalTrials":131,"cells":1278},"Zolpidem",{"EARLY_PHASE1":1279,"PHASE1":1299,"PHASE2":1301,"PHASE3":1303,"PHASE4":1305,"NA":1307},{"trials":1280,"activeCount":97},[1281,1289],{"nctId":1282,"briefTitle":1283,"status":126,"phases":1284,"primaryCompletion":1285,"completion":1286,"start":441,"enrollment":22,"conditions":1287,"interventions":1288},"NCT01809626","Proton MRS Study of SSRI-Zolpidem Interactions",[85],"2012-09","2012-12",[21],[1277],{"nctId":1290,"briefTitle":1291,"status":1171,"phases":1292,"primaryCompletion":1293,"completion":1293,"start":886,"enrollment":25,"conditions":1294,"interventions":1296},"NCT01747590","Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T",[85],"2013-12",[1295],"Psychotropic Drugs Effects",[1277,1297,1298],"Alprazolam","Caffeine",{"trials":1300,"activeCount":97},[],{"trials":1302,"activeCount":97},[],{"trials":1304,"activeCount":97},[],{"trials":1306,"activeCount":97},[],{"trials":1308,"activeCount":97},[],{"intervention":135,"totalTrials":93,"cells":1310},{"EARLY_PHASE1":1311,"PHASE1":1317,"PHASE2":1319,"PHASE3":1321,"PHASE4":1323,"NA":1325},{"trials":1312,"activeCount":97},[1313],{"nctId":124,"briefTitle":125,"status":126,"phases":1314,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":1315,"interventions":1316},[85],[24,18],[134,135,134],{"trials":1318,"activeCount":97},[],{"trials":1320,"activeCount":97},[],{"trials":1322,"activeCount":97},[],{"trials":1324,"activeCount":97},[],{"trials":1326,"activeCount":97},[],{"intervention":1298,"totalTrials":93,"cells":1328},{"EARLY_PHASE1":1329,"PHASE1":1335,"PHASE2":1337,"PHASE3":1339,"PHASE4":1341,"NA":1343},{"trials":1330,"activeCount":97},[1331],{"nctId":1290,"briefTitle":1291,"status":1171,"phases":1332,"primaryCompletion":1293,"completion":1293,"start":886,"enrollment":25,"conditions":1333,"interventions":1334},[85],[1295],[1277,1297,1298],{"trials":1336,"activeCount":97},[],{"trials":1338,"activeCount":97},[],{"trials":1340,"activeCount":97},[],{"trials":1342,"activeCount":97},[],{"trials":1344,"activeCount":97},[],{"intervention":1346,"totalTrials":119,"cells":1347},"Intravenous Nicotine",{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1352,"PHASE3":1354,"PHASE4":1356,"NA":1358},{"trials":1349,"activeCount":97},[],{"trials":1351,"activeCount":97},[],{"trials":1353,"activeCount":97},[],{"trials":1355,"activeCount":97},[],{"trials":1357,"activeCount":97},[],{"trials":1359,"activeCount":97},[1360,1368,1375,1381],{"nctId":1361,"briefTitle":1362,"status":236,"phases":1363,"primaryCompletion":1364,"completion":1364,"start":372,"enrollment":97,"conditions":1365,"interventions":1366},"NCT01589068","Effects of Progesterone on IV Nicotine Induced Changes on BOLD fMRI Signal, Hormones and Subjective Ratings of Stimulant Drugs",[90],"2015-12-01",[27],[1346,1367],"Progesterone",{"nctId":1369,"briefTitle":1370,"status":236,"phases":1371,"primaryCompletion":1364,"completion":1364,"start":1372,"enrollment":97,"conditions":1373,"interventions":1374},"NCT01589081","Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect",[90],"2008-09",[27],[1346,1367],{"nctId":1376,"briefTitle":1377,"status":236,"phases":1378,"primaryCompletion":1364,"completion":1364,"start":1093,"enrollment":97,"conditions":1379,"interventions":1380},"NCT01589055","IV Nicotine Induced Changes in Hormone Function, Mood States and Behavior",[90],[27],[1346],{"nctId":1382,"briefTitle":1383,"status":126,"phases":1384,"primaryCompletion":1385,"completion":682,"start":1386,"enrollment":456,"conditions":1387,"interventions":1388},"NCT01588561","Nicotine Related Brain Activity: The Influence of Smoking History and Blood Nicotine Levels",[90],"2015-07","2005-10",[27],[1346],{"intervention":516,"totalTrials":131,"cells":1390},{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1395,"PHASE3":1397,"PHASE4":1399,"NA":1405},{"trials":1392,"activeCount":97},[],{"trials":1394,"activeCount":97},[],{"trials":1396,"activeCount":97},[],{"trials":1398,"activeCount":97},[],{"trials":1400,"activeCount":97},[1401],{"nctId":509,"briefTitle":510,"status":126,"phases":1402,"primaryCompletion":512,"completion":512,"start":347,"enrollment":513,"conditions":1403,"interventions":1404},[89],[15],[516,496],{"trials":1406,"activeCount":97},[1407],{"nctId":1408,"briefTitle":1409,"status":126,"phases":1410,"primaryCompletion":934,"completion":934,"start":1411,"enrollment":1412,"conditions":1413,"interventions":1414},"NCT00245557","Magnetic Resonance Imaging Study of Geriatric Depression",[90],"2004-11",43,[15],[516],{"intervention":1367,"totalTrials":131,"cells":1416},{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1421,"PHASE3":1423,"PHASE4":1425,"NA":1427},{"trials":1418,"activeCount":97},[],{"trials":1420,"activeCount":97},[],{"trials":1422,"activeCount":97},[],{"trials":1424,"activeCount":97},[],{"trials":1426,"activeCount":97},[],{"trials":1428,"activeCount":97},[1429,1433],{"nctId":1361,"briefTitle":1362,"status":236,"phases":1430,"primaryCompletion":1364,"completion":1364,"start":372,"enrollment":97,"conditions":1431,"interventions":1432},[90],[27],[1346,1367],{"nctId":1369,"briefTitle":1370,"status":236,"phases":1434,"primaryCompletion":1364,"completion":1364,"start":1372,"enrollment":97,"conditions":1435,"interventions":1436},[90],[27],[1346,1367],{"intervention":1438,"totalTrials":131,"cells":1439},"Ketamine",{"EARLY_PHASE1":1440,"PHASE1":1442,"PHASE2":1444,"PHASE3":1453,"PHASE4":1455,"NA":1457},{"trials":1441,"activeCount":97},[],{"trials":1443,"activeCount":97},[],{"trials":1445,"activeCount":97},[1446],{"nctId":1447,"briefTitle":1448,"status":206,"phases":1449,"primaryCompletion":1450,"completion":1450,"start":607,"enrollment":93,"conditions":1451,"interventions":1452},"NCT02234011","A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder",[87],"2016-01",[1006],[1438],{"trials":1454,"activeCount":97},[],{"trials":1456,"activeCount":97},[],{"trials":1458,"activeCount":97},[1459],{"nctId":1460,"briefTitle":1461,"status":1171,"phases":1462,"primaryCompletion":1463,"completion":1464,"start":1465,"enrollment":19,"conditions":1466,"interventions":1467},"NCT05209217","Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder",[],"2022-12-31","2023-01-15","2019-06-04",[18],[1438],{"intervention":1469,"totalTrials":131,"cells":1470},"Riluzole",{"EARLY_PHASE1":1471,"PHASE1":1482,"PHASE2":1484,"PHASE3":1486,"PHASE4":1488,"NA":1490},{"trials":1472,"activeCount":97},[1473],{"nctId":1474,"briefTitle":1475,"status":126,"phases":1476,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":19,"conditions":1479,"interventions":1481},"NCT04630444","Riluzole Effects on Hippocampus Biomarkers",[85],"2019-03-16","2017-03-16",[1480],"Posttraumatic Stress Disorder",[1469],{"trials":1483,"activeCount":97},[],{"trials":1485,"activeCount":97},[],{"trials":1487,"activeCount":97},[],{"trials":1489,"activeCount":97},[],{"trials":1491,"activeCount":97},[1492],{"nctId":1493,"briefTitle":1494,"status":126,"phases":1495,"primaryCompletion":1496,"completion":1497,"start":1498,"enrollment":22,"conditions":1499,"interventions":1500},"NCT00544544","Riluzole in the Treatment of Bipolar Depression",[90],"2009-06","2009-07","2007-06",[29],[1469],{"intervention":1502,"totalTrials":131,"cells":1503},"Lamotrigine",{"EARLY_PHASE1":1504,"PHASE1":1506,"PHASE2":1508,"PHASE3":1510,"PHASE4":1512,"NA":1524},{"trials":1505,"activeCount":97},[],{"trials":1507,"activeCount":97},[],{"trials":1509,"activeCount":97},[],{"trials":1511,"activeCount":97},[],{"trials":1513,"activeCount":97},[1514],{"nctId":1515,"briefTitle":1516,"status":126,"phases":1517,"primaryCompletion":1518,"completion":1518,"start":1519,"enrollment":1520,"conditions":1521,"interventions":1523},"NCT00634062","Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder",[89],"2007-09","2004-12",28,[1522],"Borderline Personality Disorder",[1502],{"trials":1525,"activeCount":97},[1526],{"nctId":1527,"briefTitle":1528,"status":126,"phases":1529,"primaryCompletion":886,"completion":775,"start":538,"enrollment":1530,"conditions":1531,"interventions":1532},"NCT00720473","Lamotrigine Therapy in Geriatric Bipolar Depression",[90],69,[29],[1502],{"intervention":1534,"totalTrials":131,"cells":1535},"CoEnzyme Q10",{"EARLY_PHASE1":1536,"PHASE1":1538,"PHASE2":1540,"PHASE3":1542,"PHASE4":1544,"NA":1546},{"trials":1537,"activeCount":97},[],{"trials":1539,"activeCount":97},[],{"trials":1541,"activeCount":97},[],{"trials":1543,"activeCount":97},[],{"trials":1545,"activeCount":97},[],{"trials":1547,"activeCount":97},[1548,1557],{"nctId":1549,"briefTitle":1550,"status":126,"phases":1551,"primaryCompletion":1552,"completion":1552,"start":1553,"enrollment":1554,"conditions":1555,"interventions":1556},"NCT00720369","CoQ10 in Geriatric Bipolar Depression",[90],"2010-03","2008-07",42,[29],[1534],{"nctId":1558,"briefTitle":1559,"status":126,"phases":1560,"primaryCompletion":1561,"completion":1561,"start":886,"enrollment":373,"conditions":1562,"interventions":1563},"NCT01390389","Exploring the Effects of Coenzyme Q10 on Bioenergetics Metabolism in Geriatric Bipolar Depression",[90],"2012-07",[29],[1564],"Coenzyme Q10",{"intervention":1297,"totalTrials":131,"cells":1566},{"EARLY_PHASE1":1567,"PHASE1":1573,"PHASE2":1575,"PHASE3":1577,"PHASE4":1579,"NA":1581},{"trials":1568,"activeCount":97},[1569],{"nctId":1290,"briefTitle":1291,"status":1171,"phases":1570,"primaryCompletion":1293,"completion":1293,"start":886,"enrollment":25,"conditions":1571,"interventions":1572},[85],[1295],[1277,1297,1298],{"trials":1574,"activeCount":97},[],{"trials":1576,"activeCount":97},[],{"trials":1578,"activeCount":97},[],{"trials":1580,"activeCount":97},[],{"trials":1582,"activeCount":97},[1583],{"nctId":1584,"briefTitle":1585,"status":206,"phases":1586,"primaryCompletion":1293,"completion":1293,"start":1587,"enrollment":9,"conditions":1588,"interventions":1590},"NCT01577706","Spectroscopic Imaging at 4T: A Drug Challenge Study",[90],"2013-06",[1589],"AOD Effects and Consequences",[1297,1591],"Dextroamphetamine",{"intervention":1593,"totalTrials":93,"cells":1594},"Methylphenidate",{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1599,"PHASE3":1601,"PHASE4":1603,"NA":1605},{"trials":1596,"activeCount":97},[],{"trials":1598,"activeCount":97},[],{"trials":1600,"activeCount":97},[],{"trials":1602,"activeCount":97},[],{"trials":1604,"activeCount":97},[],{"trials":1606,"activeCount":97},[1607],{"nctId":1608,"briefTitle":1609,"status":126,"phases":1610,"primaryCompletion":1611,"completion":1611,"start":1612,"enrollment":1613,"conditions":1614,"interventions":1616},"NCT02855229","Novel Cross-Species Neurophysiological Assays of Reward and Cognitive Domains",[],"2021-08-31","2020-08-15",222,[1615],"Translational Electrophysiology",[1593],{"intervention":1618,"totalTrials":93,"cells":1619},"Marihuana",{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1624,"PHASE3":1626,"PHASE4":1628,"NA":1630},{"trials":1621,"activeCount":97},[],{"trials":1623,"activeCount":97},[],{"trials":1625,"activeCount":97},[],{"trials":1627,"activeCount":97},[],{"trials":1629,"activeCount":97},[],{"trials":1631,"activeCount":97},[1632],{"nctId":1633,"briefTitle":1634,"status":126,"phases":1635,"primaryCompletion":1636,"completion":1637,"start":1638,"enrollment":684,"conditions":1639,"interventions":1642},"NCT05384470","Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry",[],"2024-03-19","2024-08-15","2021-08-01",[1640,832,1641],"Opiate Abuse","Diagnostic",[1618],{"intervention":1644,"totalTrials":93,"cells":1645},"Nicotine + Alcohol",{"EARLY_PHASE1":1646,"PHASE1":1648,"PHASE2":1650,"PHASE3":1652,"PHASE4":1654,"NA":1656},{"trials":1647,"activeCount":97},[],{"trials":1649,"activeCount":97},[],{"trials":1651,"activeCount":97},[],{"trials":1653,"activeCount":97},[],{"trials":1655,"activeCount":97},[],{"trials":1657,"activeCount":97},[1658],{"nctId":1659,"briefTitle":1660,"status":126,"phases":1661,"primaryCompletion":1662,"completion":1662,"start":1663,"enrollment":25,"conditions":1664,"interventions":1666},"NCT02049268","Neural Mechanisms Underlying Nicotine and Alcohol Combinations",[90],"2015-12","2013-07",[1665],"Focus: Effects of Nicotine and Alcohol on Brain Circuits",[1644,1667],"Nicotine + Placebo Alcohol",{"intervention":1667,"totalTrials":93,"cells":1669},{"EARLY_PHASE1":1670,"PHASE1":1672,"PHASE2":1674,"PHASE3":1676,"PHASE4":1678,"NA":1680},{"trials":1671,"activeCount":97},[],{"trials":1673,"activeCount":97},[],{"trials":1675,"activeCount":97},[],{"trials":1677,"activeCount":97},[],{"trials":1679,"activeCount":97},[],{"trials":1681,"activeCount":97},[1682],{"nctId":1659,"briefTitle":1660,"status":126,"phases":1683,"primaryCompletion":1662,"completion":1662,"start":1663,"enrollment":25,"conditions":1684,"interventions":1685},[90],[1665],[1644,1667],{"intervention":1687,"totalTrials":93,"cells":1688},"Addition of prazosin to usual care",{"EARLY_PHASE1":1689,"PHASE1":1691,"PHASE2":1693,"PHASE3":1695,"PHASE4":1697,"NA":1699},{"trials":1690,"activeCount":97},[],{"trials":1692,"activeCount":97},[],{"trials":1694,"activeCount":97},[],{"trials":1696,"activeCount":97},[],{"trials":1698,"activeCount":97},[],{"trials":1700,"activeCount":97},[1701],{"nctId":1702,"briefTitle":1703,"status":236,"phases":1704,"primaryCompletion":1705,"completion":1705,"start":1706,"enrollment":97,"conditions":1707,"interventions":1710},"NCT01621165","Prazosin as an Antimanic Agent in Severe Mania or Mixed States",[90],"2009-11","2009-03",[1708,1709],"Bipolar, Mania","Bipolar, Mixed State",[1687],{"intervention":1712,"totalTrials":93,"cells":1713},"Phlebotomy - Folate",{"EARLY_PHASE1":1714,"PHASE1":1716,"PHASE2":1718,"PHASE3":1720,"PHASE4":1722,"NA":1724},{"trials":1715,"activeCount":97},[],{"trials":1717,"activeCount":97},[],{"trials":1719,"activeCount":97},[],{"trials":1721,"activeCount":97},[],{"trials":1723,"activeCount":97},[],{"trials":1725,"activeCount":97},[1726],{"nctId":1727,"briefTitle":1728,"status":126,"phases":1729,"primaryCompletion":1730,"completion":1731,"start":1732,"enrollment":1733,"conditions":1734,"interventions":1736},"NCT03113890","McLean and Genomind Prospective Study",[90],"2019-07-12","2020-07-31","2017-09-22",75,[15,1735],"PTSD",[1712,1737],"Cheek Swab",{"intervention":1737,"totalTrials":93,"cells":1739},{"EARLY_PHASE1":1740,"PHASE1":1742,"PHASE2":1744,"PHASE3":1746,"PHASE4":1748,"NA":1750},{"trials":1741,"activeCount":97},[],{"trials":1743,"activeCount":97},[],{"trials":1745,"activeCount":97},[],{"trials":1747,"activeCount":97},[],{"trials":1749,"activeCount":97},[],{"trials":1751,"activeCount":97},[1752],{"nctId":1727,"briefTitle":1728,"status":126,"phases":1753,"primaryCompletion":1730,"completion":1731,"start":1732,"enrollment":1733,"conditions":1754,"interventions":1755},[90],[15,1735],[1712,1737],{"intervention":1757,"totalTrials":93,"cells":1758},"Seroquel XR",{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1763,"PHASE3":1765,"PHASE4":1767,"NA":1769},{"trials":1760,"activeCount":97},[],{"trials":1762,"activeCount":97},[],{"trials":1764,"activeCount":97},[],{"trials":1766,"activeCount":97},[],{"trials":1768,"activeCount":97},[],{"trials":1770,"activeCount":97},[1771],{"nctId":1772,"briefTitle":1773,"status":206,"phases":1774,"primaryCompletion":1775,"completion":1775,"start":1776,"enrollment":1777,"conditions":1778,"interventions":1780},"NCT01066143","Generalized Anxiety and Seroquel",[90],"2013-02","2010-02",8,[1779,1757],"Generalized Anxiety Disorder",[1757],{"intervention":1782,"totalTrials":93,"cells":1783},"SAMe",{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1788,"PHASE3":1790,"PHASE4":1792,"NA":1794},{"trials":1785,"activeCount":97},[],{"trials":1787,"activeCount":97},[],{"trials":1789,"activeCount":97},[],{"trials":1791,"activeCount":97},[],{"trials":1793,"activeCount":97},[],{"trials":1795,"activeCount":97},[1796],{"nctId":1797,"briefTitle":1798,"status":126,"phases":1799,"primaryCompletion":1800,"completion":1800,"start":1372,"enrollment":16,"conditions":1801,"interventions":1802},"NCT00762268","A Trial of SAMe for Treatment-Resistant Bipolar Depression",[90],"2011-09",[18,21,29],[1782],{"intervention":1591,"totalTrials":93,"cells":1804},{"EARLY_PHASE1":1805,"PHASE1":1807,"PHASE2":1809,"PHASE3":1811,"PHASE4":1813,"NA":1815},{"trials":1806,"activeCount":97},[],{"trials":1808,"activeCount":97},[],{"trials":1810,"activeCount":97},[],{"trials":1812,"activeCount":97},[],{"trials":1814,"activeCount":97},[],{"trials":1816,"activeCount":97},[1817],{"nctId":1584,"briefTitle":1585,"status":206,"phases":1818,"primaryCompletion":1293,"completion":1293,"start":1587,"enrollment":9,"conditions":1819,"interventions":1820},[90],[1589],[1297,1591]]